Shah Wealth Advisors LLC Buys New Position in CRISPR Therapeutics AG $CRSP

Shah Wealth Advisors LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 69,060 shares of the company's stock, valued at approximately $3,767,000. CRISPR Therapeutics makes up approximately 0.9% of Shah Wealth Advisors LLC's holdings, making the stock its 23rd largest holding. Shah Wealth Advisors LLC owned approximately 0.07% of CRISPR Therapeutics at the end of the most recent reporting period.

• 3 Biotech Stocks That Could Benefit from the Patent Cliff

A number of other institutional investors have also recently made changes to their positions in the stock. Royal Bank of Canada grew its position in CRISPR Therapeutics by 28.2% in the first quarter. Royal Bank of Canada now owns 142,696 shares of the company's stock worth $4,856,000 after acquiring an additional 31,392 shares in the last quarter. AQR Capital Management LLC purchased a new stake in CRISPR Therapeutics during the first quarter valued at about $861,000. Woodline Partners LP lifted its stake in CRISPR Therapeutics by 34.3% during the first quarter. Woodline Partners LP now owns 136,483 shares of the company's stock worth $4,645,000 after purchasing an additional 34,883 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of CRISPR Therapeutics in the 2nd quarter worth about $237,000. Finally, Invesco Ltd. boosted its holdings in shares of CRISPR Therapeutics by 138.4% in the 2nd quarter. Invesco Ltd. now owns 66,648 shares of the company's stock worth $3,242,000 after purchasing an additional 38,691 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Citizens Jmp reiterated a "market outperform" rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Sanford C. Bernstein boosted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $68.06.

• CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Read Our Latest Research Report on CRISPR Therapeutics

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $55.79 on Friday. The company has a market capitalization of $5.39 billion, a P/E ratio of -11.72 and a beta of 1.76. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The stock has a 50 day moving average price of $53.86 and a two-hundred day moving average price of $52.95.

• CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The firm had revenue of $10.18 million during the quarter. Analysts expect that CRISPR Therapeutics AG will post -4.47 earnings per share for the current year.

CRISPR Therapeutics Profile

(Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Further Reading

• Five stocks we like better than CRISPR Therapeutics
• Revolution Medicines Got Its Breakthrough—What Moves It Next?
• Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
• FB Financial's Southern Expansion and Buybacks Drive Analyst Optimism
• AST SpaceMobile Stock Soared 12%—This Was the Catalyst

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CRISPR Therapeutics Right Now?

Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here